Ming P. Zhao

651 Dongfeng East Road
Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 82 publications

Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma: The Phase 3 TORCH Randomized Clinical Trial.

Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma: The Phase 3 TORCH Randomized Clinical Trial.

Journal: JAMA oncology

Published: July 30, 2026

On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial.

On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial.

Journal: The lancet. Gastroenterology & hepatology

Published: May 07, 2026

Evaluation of the predictive accuracy of nine staging systems in patients with hepatocellular carcinoma: a multicenter, retrospective study in China.

Evaluation of the predictive accuracy of nine staging systems in patients with hepatocellular carcinoma: a multicenter, retrospective study in China.

Journal: Scientific reports

Published: March 01, 2026

Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in the Era of Systemic Therapies (2020-2025).

Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in the Era of Systemic Therapies (2020-2025).

Journal: Liver cancer

Published: October 12, 2025

Hepatic Artery Infusion Chemotherapy for Cholangiocarcinoma in 2025.

Hepatic Artery Infusion Chemotherapy for Cholangiocarcinoma in 2025.

Journal: Liver cancer

Published: October 08, 2025

Tescalcin is a phagocytic checkpoint driving immune escape and limiting immunotherapeutic efficacy in hepatocellular carcinoma.

Tescalcin is a phagocytic checkpoint driving immune escape and limiting immunotherapeutic efficacy in hepatocellular carcinoma.

Journal: The Journal of clinical investigation

Published: September 23, 2025

Hepatocellular carcinoma surveillance: a health economic evaluation.

Hepatocellular carcinoma surveillance: a health economic evaluation.

Journal: Clinical and molecular hepatology

Published: September 19, 2025

Concomitant medication use and clinical outcome in hepatocellular carcinoma treated with immune-based therapy: a multicenter analysis.

Concomitant medication use and clinical outcome in hepatocellular carcinoma treated with immune-based therapy: a multicenter analysis.

Journal: Frontiers in immunology

Published: August 13, 2025

Beyond diagnostic accuracy: Economic and clinical considerations for NC-MRI in late HCC recurrence surveillance: Letter to the editor on "Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparison to contrast-enhanced computed tomography".

Beyond diagnostic accuracy: Economic and clinical considerations for NC-MRI in late HCC recurrence surveillance: Letter to the editor on "Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparison to contrast-enhanced computed tomography".

Journal: Clinical and molecular hepatology

Published: July 13, 2025

Interventional arterial chemotherapy versus sorafenib for advanced hepatocellular carcinoma in China: a health economic evaluation of open-label, randomised, phase 3 study.

Interventional arterial chemotherapy versus sorafenib for advanced hepatocellular carcinoma in China: a health economic evaluation of open-label, randomised, phase 3 study.

Journal: BMJ open

Published: May 28, 2025

TACE-HAIC versus TACE as Initial Regional Therapy for Unresectable Huge Hepatocellular Carcinoma (>10 cm): A Propensity Score-Matched Study.

TACE-HAIC versus TACE as Initial Regional Therapy for Unresectable Huge Hepatocellular Carcinoma (>10 cm): A Propensity Score-Matched Study.

Journal: Journal of hepatocellular carcinoma

Published: May 18, 2025

Children's hepatoblastoma: gender and infant age demand focus in the global burden of disease study 2021.

Children's hepatoblastoma: gender and infant age demand focus in the global burden of disease study 2021.

Journal: Hepatology international

Published: May 07, 2025

Showing 1-12 of 82

Last Updated: 09/26/2026